These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 10645036

  • 1. Enalapril treatment of proteinuria in normotensive children.
    Sasinka MA, Podracka L, Boor A, Jurkovic I, Mitro A, Kovacs L.
    Bratisl Lek Listy; 1999 Sep; 100(9):476-80. PubMed ID: 10645036
    [Abstract] [Full Text] [Related]

  • 2. Enalapril and prednisone in children with nephrotic-range proteinuria.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA.
    Pediatr Nephrol; 2000 Oct; 14(12):1088-91. PubMed ID: 11045392
    [Abstract] [Full Text] [Related]

  • 3. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
    Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM.
    Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
    [Abstract] [Full Text] [Related]

  • 4. Enalapril: antiproteinuric effect in children with nephrotic syndrome.
    Lama G, Luongo I, Piscitelli A, Salsano ME.
    Clin Nephrol; 2000 Jun; 53(6):432-6. PubMed ID: 10879662
    [Abstract] [Full Text] [Related]

  • 5. Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.
    Nakhoul F, Khankin E, Yaccob A, Kawachi H, Karram T, Awaad H, Nakhoul N, Hoffman A, Abassi Z.
    Am J Physiol Renal Physiol; 2008 Mar; 294(3):F628-37. PubMed ID: 18094029
    [Abstract] [Full Text] [Related]

  • 6. Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.
    Nakhoul F, Ramadan R, Khankin E, Yaccob A, Kositch Z, Lewin M, Assady S, Abassi Z.
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F880-90. PubMed ID: 15942045
    [Abstract] [Full Text] [Related]

  • 7. [Effect of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome].
    Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M.
    Cas Lek Cesk; 1999 Oct 20; 138(18):560-4. PubMed ID: 10596472
    [Abstract] [Full Text] [Related]

  • 8. Losartan and enalapril are comparable in reducing proteinuria in children.
    Webb NJ, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C.
    Kidney Int; 2012 Oct 20; 82(7):819-26. PubMed ID: 22739977
    [Abstract] [Full Text] [Related]

  • 9. Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.
    Caletti MG, Balestracci A, Missoni M, Vezzani C.
    Pediatr Nephrol; 2013 May 20; 28(5):745-50. PubMed ID: 23250713
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
    Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll HK, Wallner M, Auinger M, Arias I, Schneider B, Mayer G.
    Kidney Blood Press Res; 1998 May 20; 21(1):66-9. PubMed ID: 9661139
    [Abstract] [Full Text] [Related]

  • 11. Long-term therapy with enalapril in patients with nephrotic-range proteinuria.
    Proesmans W, Wambeke IV, Dyck MV.
    Pediatr Nephrol; 1996 Oct 20; 10(5):587-9. PubMed ID: 8897561
    [Abstract] [Full Text] [Related]

  • 12. [The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria].
    Liern M, Dieguez SM, De Reyes V, Vallejos G, Canepa C.
    Nefrologia; 2004 Oct 20; 24(6):553-8. PubMed ID: 15683027
    [Abstract] [Full Text] [Related]

  • 13. Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria.
    Székács B, Vajo Z, Dachman W.
    Acta Physiol Hung; 1996 Oct 20; 84(4):361-7. PubMed ID: 9328608
    [Abstract] [Full Text] [Related]

  • 14. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M, Tylicki L, Rutkowski P, Rutkowski B.
    Scand J Urol Nephrol; 2004 Oct 20; 38(5):427-33. PubMed ID: 15764256
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J, Abitbol C, Montané B, Zilleruelo G.
    Nephrol Dial Transplant; 2007 May 20; 22(5):1332-7. PubMed ID: 17299000
    [Abstract] [Full Text] [Related]

  • 16. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
    Cetinkaya R, Odabas AR, Selcuk Y.
    Int J Clin Pract; 2004 May 20; 58(5):432-5. PubMed ID: 15206496
    [Abstract] [Full Text] [Related]

  • 17. [The antiproteinuric action of angiotensin-converting enzyme inhibitors in chronic glomerulonephritis and diabetic nephropathy].
    Kutyrina IM, Tareeva IE, Shestakova MV, Gerasimenko OI, Zverev KV, Rogov VA, Sheremet'eva OV.
    Ter Arkh; 1994 May 20; 66(6):19-22. PubMed ID: 7940357
    [Abstract] [Full Text] [Related]

  • 18. Nephropathy of cyanotic congenital heart disease: clinical characteristics and effectiveness of an angiotensin-converting enzyme inhibitor.
    Fujimoto Y, Matsushima M, Tsuzuki K, Okada M, Shibata M, Yanase Y, Usui K, Nagashima M.
    Clin Nephrol; 2002 Aug 20; 58(2):95-102. PubMed ID: 12227694
    [Abstract] [Full Text] [Related]

  • 19. Influence of losartan and enalapril on urinary excretion of 8-isoprostane in experimental nephrotic syndrome.
    Tesar V, Zima T, Jirsa M, Crkovská J, Stípek S, Vernerová Z, Seráková M.
    Med Sci Monit; 2002 Feb 20; 8(2):BR69-74. PubMed ID: 11859270
    [Abstract] [Full Text] [Related]

  • 20. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats.
    Song J, Meng L, Li S, Qu L, Li X.
    Vascul Pharmacol; 2009 Feb 20; 50(5-6):185-93. PubMed ID: 19563735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.